Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Prospect Venture Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
5,636,351Website Global Rank
1,670Website Monthly Traffic
Twitter Followers
Description
Prospect Venture Partners is a venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prospect targets commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovative technologies with the potential for significant investment returns. The firm invests in companies with a wide variety of development and financing requirements including new company incubations, first and second venture financing rounds, and later stage private and public companies with proven business models requiring expansion capital.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2005 | Vitae Pharmaceuticals | Series C | 15M |
| 4/2007 | Cogentus Pharmaceuticals | Series B | 15M |
| 2/2012 | Satori Pharmaceuticals | Venture Round | 15M |
| 10/2004 | Gloucester Pharmaceuticals | Series B | 29M |
| 3/2014 | Element Science | Series A | 12.5M |
| 11/2007 | Vitae Pharmaceuticals | Series D | 15M |
| 3/2004 | Jazz Pharmaceuticals | Series B | 0 |
| 10/2011 | Azelon Pharmaceuticals | Series A | 4.5M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 11/2006 | Amira Pharmaceuticals | Series A | 4M |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 1/2004 | Vitae Pharmaceuticals | Series B | 15M |
| 9/2004 | Allux Medical | Series A | 800k |
| 10/2011 | Topica Pharmaceuticals | Series B | 27M |
| 5/2005 | AVEO Oncology | Series C | 5M |
| 2/2007 | Visiogen | Venture Round | 24M |
| 3/2014 | NinePoint Medical | Series B | 34M |
| 8/2002 | Biospect | Series A | 4M |
| 1/2010 | DFine | Venture Round | 0 |
| 11/2011 | DFine | Venture Round | 25M |
| 6/2003 | Opus Medical | Series C | 13.6M |
| 6/2007 | Roxro Pharma | Series B | 42.7M |
| 10/2005 | Roxro Pharma | Series B | 21.6M |
| 3/2002 | Signature BioScience | Series E | 0 |
| 1/2009 | DFine | Venture Round | 0 |
| 1/2011 | SurePoint Medical | Venture Round | - |
| 8/2002 | Archemix | Series A | 51.8M |
| 8/2009 | Gloucester Pharmaceuticals | Series D | 29M |
| 4/2007 | Aspen MedTech | Venture Round | 1M |
| 3/2008 | SurgRx | Series G | 19.8M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 11/2005 | Nanosys | Series C | 0 |
| 6/2004 | Rejuvenon | Series B | 37M |
| 7/2010 | DFine | Venture Round | 36.2M |
| 8/2010 | Complete Genomics | Series E | 39M |
| 9/2004 | SurgRx | Series D | 11.9M |
| 11/2011 | NGM Biopharmaceuticals | Series B | 55.4M |
| 6/2012 | SentreHEART | Series C | 26M |
| 4/2007 | SurgRx | Series F | 20M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 1/2010 | Neomend | Series D | 30M |
| 9/2008 | Baxano | Series B | 20M |
| 7/2007 | Neomend | Series C | 6M |
| 10/2010 | NinePoint Medical | Series A | 33M |
| 1/2009 | Satori Pharmaceuticals | Series A | 22M |
| 3/2004 | Phylogix Inc. | Series B | 12M |
| 4/2004 | Archemix | Series B | 50M |
| 2/2002 | Nanosys | Series A | 15M |
| 10/2010 | Pathwork Diagnostics | Series C | 30M |
| 6/2010 | Baxano | Series C | 30M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 10/2009 | Lux Biosciences | Series B | 50M |
| 6/2002 | Infinity Pharmaceuticals | Series B | 0 |
| 8/2009 | Complete Genomics | Series D | 45M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 8/2003 | Rinat Neuroscience | Series B | 40M |
| 9/2006 | Alvine Pharmaceuticals | Series A | 21.5M |
| 7/2003 | Tercica | Series B | 44M |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
| 4/2003 | Nanosys | Series B | 0 |
| 8/2005 | Amira Pharmaceuticals | Series A | 3M |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 12/2007 | Cogentus Pharmaceuticals | Series C | 62.5M |
| 1/2011 | Satori Pharmaceuticals | Series B | 7M |
| 10/2003 | AVEO Oncology | Series B | 42.7M |
| 4/2008 | Transave | Series D | 35M |
| 5/2002 | AVEO Oncology | Series A | 15M |
| 3/2015 | NGM Biopharmaceuticals | Series D | 57.5M |
| 7/2013 | NGM Biopharmaceuticals | Series C | 50M |
| 9/2016 | SentreHEART | Series D | 35M |
| 5/2006 | Cogentus Pharmaceuticals | Series A | - |
| 9/2006 | Alvine Pharmaceuticals | Series A | 8M |
| 10/2004 | Vanda Pharmaceuticals | Series B | 18.5M |
| 11/2005 | Hansen Medical | Venture Round | - |
| 5/2009 | Visiogen | Series D | 40M |
| 12/2009 | NGM Biopharmaceuticals | Series A | 26.6M |
| 4/2005 | Allux Medical | Series B | 5M |
| 2/2002 | Metreo | Series C | 15M |
| 4/2008 | DFine | Series D | 20M |
| 12/2005 | DFine | Series B | 6.5M |
| 3/2007 | Amira Pharmaceuticals | Series B | 25M |
| 7/2006 | Pathwork Diagnostics | Venture Round | 11M |
| 9/2016 | SentreHEART | Series D | 0 |
| 3/2015 | NGM Biopharmaceuticals | Series D | 0 |
| 4/2014 | Nora Therapeutics | Series B | 0 |
| 3/2014 | Element Science | Series A | 0 |
| 3/2014 | NinePoint Medical | Series B | 0 |
| 7/2013 | NGM Biopharmaceuticals | Series C | 0 |
| 6/2012 | SentreHEART | Series C | 0 |
| 2/2012 | Satori Pharmaceuticals | Venture Round | 0 |
| 11/2011 | DFine | Venture Round | 0 |
| 11/2011 | NGM Biopharmaceuticals | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
